2022
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patientsCardiovascular Benefit of Continuous Positive Airway Pressure in Adults with Coronary Artery Disease and Obstructive Sleep Apnea without Excessive Sleepiness.
Azarbarzin A, Zinchuk A, Wellman A, Labarca G, Vena D, Gell L, Messineo L, White DP, Gottlieb DJ, Redline S, Peker Y, Sands SA. Cardiovascular Benefit of Continuous Positive Airway Pressure in Adults with Coronary Artery Disease and Obstructive Sleep Apnea without Excessive Sleepiness. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 767-774. PMID: 35579605, PMCID: PMC9799106, DOI: 10.1164/rccm.202111-2608oc.Peer-Reviewed Original ResearchConceptsContinuous positive airway pressureObstructive sleep apneaAdverse cardiovascular outcomesPositive airway pressureCardiovascular outcomesAirway pressureCardiovascular benefitsCardiovascular riskSleep apneaExcessive sleepinessEffect of CPAPMultivariable Cox regressionProspective clinical trialsCoronary artery diseaseGreater cardiovascular benefitPulse rate responsesSignificant risk reductionCPAP therapyRepeat revascularizationBaseline polysomnographyCardiovascular mortalityArtery diseasePrimary outcomeCox regressionRespiratory eventsRates of In-Hospital Decongestion and Association with Mortality and Cardiovascular Outcomes Among Patients Admitted for Acute Heart Failure
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Rates of In-Hospital Decongestion and Association with Mortality and Cardiovascular Outcomes Among Patients Admitted for Acute Heart Failure. The American Journal Of Medicine 2022, 135: e337-e352. PMID: 35472391, PMCID: PMC10767835, DOI: 10.1016/j.amjmed.2022.04.003.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAcute heart failureHeart failure hospitalizationComposite outcomeHeart failureFailure hospitalizationCardiovascular outcomesCardiovascular mortalityNatriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHeart Failure Outcome StudyMultivariable Cox regression modelsResistant heart failureLower hazardCox regression modelRisk of mortalityPropensity-score matchingTolvaptan (EVEREST) trialCause mortalityCardiovascular benefitsVasopressin AntagonismVolume overloadReduced riskOutcome studiesThe Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients
Fadah K, Alashi A, Deoker A. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Current Cardiology Reports 2022, 24: 17-22. PMID: 35000149, DOI: 10.1007/s11886-021-01619-8.Peer-Reviewed Original ResearchConceptsDiabetic populationDiabetic patientsSGLT2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsMajor adverse cardiovascular eventsReal-world cohort studyPeptide-1 receptor agonistsAdditional cardiovascular benefitsGLP-1RA therapyAdverse cardiovascular eventsCotransporter 2 inhibitorsMechanism of actionGLP-1RAsAntihyperglycemic therapyCardiac complicationsCardiac mortalityCardiovascular eventsCardiac outcomesCardiovascular benefitsCohort studyDrug therapyReceptor agonistCardioprotective processesReviewCardiovascular disease
2021
Cardiovascular Benefit of CPAP Is Modified by the Sleep Apnea Related Pulse Rate Response in Coronary Artery Disease Patients with Nonsleepy OSA: Findings from the RICCADSA Randomized Controlled Trial
Azarbarzin A, Zinchuk A, Wellman D, Taranto Montemurro L, Vena D, Gell L, Messineo L, White D, Gottlieb D, Redline S, Peker Y, Sands S. Cardiovascular Benefit of CPAP Is Modified by the Sleep Apnea Related Pulse Rate Response in Coronary Artery Disease Patients with Nonsleepy OSA: Findings from the RICCADSA Randomized Controlled Trial. 2021, a1103-a1103. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1103.Peer-Reviewed Original Research
2020
SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure
2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO studyTreatment of Hypertension in Complex Older Adults: How Many Medications Are Needed?
Ouellet GM, McAvay G, Murphy TE, Tinetti ME. Treatment of Hypertension in Complex Older Adults: How Many Medications Are Needed? Gerontology And Geriatric Medicine 2019, 5: 2333721419856436. PMID: 31245434, PMCID: PMC6580710, DOI: 10.1177/2333721419856436.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsMedical Expenditure Panel SurveyAntihypertensive classesCardiovascular eventsOlder adultsMultivariable proportional hazards regressionAdverse cardiovascular eventsProportional hazards regressionGreater cardiovascular benefitTreatment of hypertensionComplex older adultsRisk of mortalityRepresentative community sampleAdditional antihypertensivesMultiple antihypertensivesHypertensive adultsCardiovascular benefitsHazards regressionExposure groupRepresentative cohortMobility disabilityInverse probabilityLongitudinal associationsHypertensionAdults
2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo groupWhat Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IRPrior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2013
Optimizing Cardiovascular Benefits of Exercise: A Review of Rodent Models
Davis B, Moriguchi T, Sumpio B. Optimizing Cardiovascular Benefits of Exercise: A Review of Rodent Models. International Journal Of Angiology 2013, 22: 013-022. PMID: 24436579, PMCID: PMC3699221, DOI: 10.1055/s-0033-1333867.Peer-Reviewed Original ResearchCardiovascular diseaseCardiovascular benefitsCardiovascular healthRodent modelsRisk of CVDRegular aerobic exerciseDuration of exerciseRodent-based studiesComponents of exerciseOptimal regimenAerobic exerciseLipid profileRodent studiesVascular structuresFurther studiesHuman subjectsExerciseDurationReviewHealthLiterature reviewOptimal typeRegimenMEDLINEStudy
2007
Depressive Symptoms and Sex Affect Completion Rates and Clinical Outcomes in Cardiac Rehabilitation
Caulin‐Glaser T, Maciejewski PK, Snow R, LaLonde M, Mazure C. Depressive Symptoms and Sex Affect Completion Rates and Clinical Outcomes in Cardiac Rehabilitation. Preventive Cardiology 2007, 10: 15-21. PMID: 17215628, DOI: 10.1111/j.1520-037.2007.05666.x.Peer-Reviewed Original ResearchConceptsBDI-II scoresClinical outcomesDepressive symptomsMultiple logistic regression analysisCardiac rehabilitation completionBody mass indexCoronary heart diseaseLogistic regression analysisSymptoms of depressionLower BDI-II scoresRehabilitation completionExercise capacityCardiac rehabilitationCardiovascular benefitsMass indexCR programCardiovascular healthHeart diseaseLipid profileSymptomsPatientsIndependent effectsWomenRegression analysisCompletion rates
2006
Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk?
LAINE L. Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk? Alimentary Pharmacology & Therapeutics 2006, 24: 897-908. PMID: 16948802, DOI: 10.1111/j.1365-2036.2006.03077.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLow-dose aspirinGastrointestinal bleedingPlacebo-controlled trialRelative riskNon-aspirin non-steroidal anti-inflammatory drugsLarge Danish cohort studyRandomized placebo-controlled trialNon-steroidal anti-inflammatory drugsAbsolute annual incidenceDanish cohort studyMajor gastrointestinal bleedingUpper gastrointestinal bleedingEnteric-coated aspirinAbsolute rate increaseAnti-inflammatory drugsEndoscopic trialsCorticosteroid useAnticoagulant therapyCardiovascular benefitsCohort studyAnnual incidenceVascular protectionClinical eventsUlcer incidenceOdds ratio
2003
Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk
Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Human Reproduction 2003, 18: 1570-1573. PMID: 12871864, DOI: 10.1093/humrep/deg330.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseFSH levelsOvarian functionRisk factorsBasal FSHCardiovascular riskDay 3 serum FSH levelsIU/Day 3 FSH levelsElevated basal FSHNormal estradiol levelsCardiac risk factorsCardiovascular risk factorsSerum FSH levelsNormal cycling womenFunctional ovarian reserveHormone replacement therapyLack of estrogenNormal menstrual cycleMajor risk factorCause of deathPremenopausal womenCardiovascular benefitsOvarian reserveSerum FSH
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply